A citation-based method for searching scientific literature

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
Times Cited: 267



Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Donald C Goff, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green. Schizophr Res 2008
Times Cited: 94




List of shared articles



Times cited

Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials.
Kah Kheng Goh, Tzu-Hua Wu, Chun-Hsin Chen, Mong-Liang Lu. J Psychopharmacol 2021
6

Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia.
Qiongqiong Wu, Jing Huang, Renrong Wu. Front Neurosci 2021
2

Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.
Ju-Chun Pei, Da-Zhong Luo, Shiang-Shin Gau, Chia-Yuan Chang, Wen-Sung Lai. Front Psychiatry 2021
1

Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia †.
Natalie de la Garrigue, Juliana Glasser, Pejman Sehatpour, Dan V Iosifescu, Elisa Dias, Marlene Carlson, Constance Shope, Tarek Sobeih, Tse-Hwei Choo, Melanie M Wall,[...]. J Psychiatr Brain Sci 2020
3

The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review.
Ragy R Girgis, Anthony W Zoghbi, Daniel C Javitt, Jeffrey A Lieberman. J Psychiatr Res 2019
39

Glutamate hypothesis in schizophrenia.
Yota Uno, Joseph T Coyle. Psychiatry Clin Neurosci 2019
105

The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
Bahareh Peyrovian, Joshua D Rosenblat, Zihang Pan, Michelle Iacobucci, Elisa Brietzke, Roger S McIntyre. Prog Neuropsychopharmacol Biol Psychiatry 2019
28

Natural Medicines for Psychotic Disorders: A Systematic Review.
H J Rogier Hoenders, Agna A Bartels-Velthuis, Nina K Vollbehr, Richard Bruggeman, Henderikus Knegtering, Joop T V M de Jong. J Nerv Ment Dis 2018
5

Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Joshua T Kantrowitz, Neal R Swerdlow, Walter Dunn, Sophia Vinogradov. Biol Psychiatry Cogn Neurosci Neuroimaging 2018
14

The Therapeutic Role of d-Cycloserine in Schizophrenia.
D Goff. Adv Pharmacol 2016
9

The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.
Samuel M Cohen, Richard W Tsien, Donald C Goff, Michael M Halassa. Schizophr Res 2015
136

Drug development in schizophrenia: are glutamatergic targets still worth aiming at?
Donald C Goff. Curr Opin Psychiatry 2015
30

Drug repurposing and emerging adjunctive treatments for schizophrenia.
Jan Malte Bumb, Frank Enning, F Markus Leweke. Expert Opin Pharmacother 2015
24

Pharmacological treatment of negative symptoms in schizophrenia.
Hans-Jürgen Möller, Pal Czobor. Eur Arch Psychiatry Clin Neurosci 2015
38

Assessing schizophrenia-relevant cognitive and social deficits in mice: a selection of mouse behavioral tasks and potential therapeutic compounds.
Wen-Sung Lai, Chia-Yuan Chang, Wan-Rong Wong, Ju-Chun Pei, Ya-Shan Chen, Wei-Li Hung. Curr Pharm Des 2014
11

Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.
Oliver Gruber, Antonella Chadha Santuccione, Helmut Aach. Front Psychiatry 2014
29


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy